Emily Lauren Ward

Ms. Emily Lauren Ward

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2026 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
EWEmily Lauren Ward
Emily Lauren Ward
SKShruthi Karnam
Shruthi Karnam
ACAmogh Changavi
Amogh Changavi
MKMatangi Kumar
Matangi Kumar
SMShubham Maurya
Shubham Maurya
JFJohn G. Flanagan
John G. Flanagan
Prostaglandin D2 (PGD2), PGE2, and other prostanoids play important roles in retinal and optic nerve (ON) health and disease, including neovascularization, neuroinflammation, and neurodegeneration. We reviewed the synthesis, expression, regulation, mechanisms, and functions of the principal prostanoids (PGF2α, PGI2, TXA2, PGE2, and PGD2) in the eye. Prostanoids can be difficult to study in-vivo or ex-vivo because they are small, unstable molecules. To address this, we incorporated lipidomics data clarifying the prostanoids present in the mouse retina and ON, and mined single-cell transcriptomic atlases of the human and mouse posterior eye to map prostanoid pathway expression across cell types. We identified species-, tissue-, and region-specific differences in prostanoid synthase and receptor expression. The PGF2α receptor (FP) was detected in mouse but not human retinal ganglion cells (RGCs). TXA2 synthase was present in ON but not retinal glia. DP2 and EP1 were enriched in microglia and astrocytes of the retrolaminar ON, but not the ON head. Analysis of mouse RGC degeneration datasets revealed dynamic regulation of prostanoid pathways in glia and RGCs. During early degeneration, macroglia upregulated PGD2 synthase (L-PGDS), while microglia upregulated the PGE2 receptor EP4. Glia downregulated intrinsic COX-1 pathways, yet we did not observe induction of COX-2. Topical NSAID treatment exacerbates RGC damage following mouse ocular hypertension, underscoring the need to clarify COX-1/2 roles in the eye. In conclusion, intrinsic prostanoid networks support retinal and ON homeostasis and are dynamically regulated in disease, representing cell-specific, receptor, and disease stage therapeutic targets, including potential RGC protection.

3 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EWEmily Lauren Ward
Emily Lauren Ward
PCPhilip E Chen
Philip E Chen
AHAlaa Hussien-Ali
Alaa Hussien-Ali
The jasmonates are a class of oxylipin phytohormones known to exhibit anti-inflammatory, antioxidant, and anti-cancer effects in mammalian cells. We investigated the ability of three jasmonate compounds (jasmonic acid, methyl jasmonate, and 12-OPDA) and two structurally distinct jasmonate precursors (alpha-linolenic acid and palmitic acid) to attenuate inflammation in an in vitro model of neurodegenerative disease, for which the mechanisms of action have not been well identified. The study modeled chronic neuroinflammation in SH-SY5Y neuroblastoma cells using exogenous prostaglandin E 2 (PGE 2 ) treatment. Prostaglandin E 2 caused concentration-dependent levels of inflammation and SH-SY5Y cell death, which were attenuated by the jasmonates and their precursors. To this end, structural similarities between the jasmonates and PGE 2 were correlated with increased potency of their anti-inflammatory effects. Downstream biomarkers of signaling through the pro-inflammatory E prostanoid receptor subtype 2 (EP2) were then quantified using enzyme-linked immunosorbent assay methods. Of the compounds tested, only jasmonic acid and methyl jasmonate attenuated inflammation in the SH-SY5Y cells via crosstalk with the PGE 2 /EP2 signaling axis. Additionally, structural models and molecular binding simulations serve as evidence for our hypothesis that JA and MeJA achieve this crosstalk through competitive inhibition of the receptor EP2. This novel finding has implications in the study of neurodegenerative diseases for which the disease pathology is related to chronic neuroinflammation, including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). In addition, these findings add to the understanding of the relationship between pro-inflammatory prostaglandin E 2 signaling and disease severity.